Among TME immune cells, CD8+ cytotoxic T cells, CD4+ T cells, TAMs, and MDSCs can be considered the major players in the immunological milieu of the BC microenvironment that significantly influence BC outcomes and clinical therapeutic results [4,5]. This evidence concerns the gene CD8A and breast cancer.